Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma

(2021) Tan Sang et al.   CANCER GENE THERAPY

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

(2020) Stuart E. Lacy et al.   BLOOD

Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells

(2020) Sophie L. Kerschner-Morales et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma

(2020) Xiangxiang Zhou et al.   Journal of Hematology & Oncology

Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine

(2020) Anwesha Dey et al.   NATURE REVIEWS DRUG DISCOVERY

An overview on anti-tubulin agents for the treatment of lymphoma patients

(2020) Marilia Barreca et al.   PHARMACOLOGY & THERAPEUTICS

The functions and clinical significance of circRNAs in hematological malignancies

(2020) Xiangxiang Zhou et al.   Journal of Hematology & Oncology

Predicting and Overcoming Taxane Chemoresistance

(2020) Sylvie Rodrigues-Ferreira et al.   TRENDS IN MOLECULAR MEDICINE

Non-mitotic functions of polo-like kinases in cancer cells

(2020) Christopher A. Raab et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Targeting mitosis exit: A brake for cancer cell proliferation

(2019) Xinran Liu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy

(2019) Kinsie E Arnst et al.   MEDICINAL RESEARCH REVIEWS

Genetic alterations and their clinical implications in DLBCL

(2019) Yi Miao et al.   Nature Reviews Clinical Oncology

Role for polo-like kinase 4 in mediation of cytokinesis

(2019) Michael F. Press et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

(2019) Zachary W. Veitch et al.   BRITISH JOURNAL OF CANCER

LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL

(2019) Salma Parvin et al.   CANCER CELL

Feedback loops in the Plk4–STIL–HsSAS6 network coordinate site selection for procentriole formation

(2019) Daisuke Takao et al.   Biology Open

Cell-Cycle Asynchrony Generates DNA Damage at Mitotic Entry in Polyploid Cells

(2019) Maddalena Nano et al.   CURRENT BIOLOGY

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

(2019) Andrea Ghelli Luserna di Rorà et al.   Journal of Hematology & Oncology

Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy

(2019) Sylvie Rodrigues-Ferreira et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Centrosome amplification arises before neoplasia and increases upon p53 loss in tumorigenesis

(2018) Carla A.M. Lopes et al.   JOURNAL OF CELL BIOLOGY

Once and only once: mechanisms of centriole duplication and their deregulation in disease

(2018) Erich A. Nigg et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

(2018) Masanori Kawakami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Polo-like kinase 4 mediates epithelial–mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway

(2018) Xiangdong Tian et al.   Cell Death & Disease

Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis

(2018) Xiao-Mei Yang et al.   GASTROENTEROLOGY

Anti-mitotic therapies in cancer

(2018) Julia Tischer et al.   JOURNAL OF CELL BIOLOGY

CFI-400945 is not a selective cellular PLK4 inhibitor

(2018) Karen Oegema et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

(2018) Zuoxin Zhang et al.   CANCER LETTERS

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies

(2017) Ankit C. Borisa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Plk4 and Aurora A cooperate in the initiation of acentriolar spindle assembly in mammalian oocytes

(2017) Leah Bury et al.   JOURNAL OF CELL BIOLOGY

Anti-mitotic agents: Are they emerging molecules for cancer treatment?

(2017) Larissa Siqueira Penna et al.   PHARMACOLOGY & THERAPEUTICS

Clinical features of diffuse large B-cell lymphoma with polyploidy

(2016) Joji Shimono et al.   PATHOLOGY INTERNATIONAL

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts

(2016) Ines Lohse et al.   Oncotarget

Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy

(2016) Zhenhua Li et al.   Journal of Cancer

Targeting Mitosis in Cancer: Emerging Strategies

(2015) Carmen Dominguez-Brauer et al.   MOLECULAR CELL

Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis

(2015) Özdemirhan Serçin et al.   NATURE CELL BIOLOGY

Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

(2014) Jacqueline M. Mason et al.   CANCER CELL

Cytokinesis Failure Triggers Hippo Tumor Suppressor Pathway Activation

(2014) Neil J. Ganem et al.   CELL

A novel role for Plk4 in regulating cell spreading and motility

(2014) C O Rosario et al.   ONCOGENE

Polo-like kinase 4 phosphorylates Chk2

(2011) Steve Petrinac et al.   CELL CYCLE

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research

(2009) E. S. Jaffe   Hematology-American Society of Hematology Education Program

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers ofin vivoresponse

(2008) Jane Houldsworth et al.   LEUKEMIA & LYMPHOMA